High throughput screening system for development of anti-cancer drugs inducing HER2 internalization

被引：0
|
作者：
Isa, Masayuki [1 ]
Asanuma, Daisuke [1 ]
Namiki, Shigeyuki [1 ]
Kumagai, Kazuo [2 ]
Kojima, Hirotatsu [2 ]
Okabe, Tajayoshi [2 ]
Nagano, Tetsuo [2 ]
Hirose, Kenzo [1 ]
机构：
[1] Univ Tokyo, Sch Med, Dept Neurobiol, Bunkyo Ku, Tokyo 1130033, Japan
[2] Univ Tokyo, Sch Med, OCDD, Bunkyo Ku, Tokyo 1130033, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2013年 / 121卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：232P / 232P
页数：1
相关论文
共 50 条
  • [31] New screening technology for development of effective anti-cancer drugs targeting telomere G-tail
    Tahara, H.
    Seimiya, H.
    Shin-ya, K.
    Ide, T.
    EJC SUPPLEMENTS, 2006, 4 (12): : 189 - 189
  • [32] An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
    Bhattarai, Deepak
    Singh, Sarbijt
    Jang, Yerin
    Han, Seung Hyeon
    Lee, Kyeong
    Choi, Yongseok
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (19) : 2156 - 2168
  • [33] Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling
    Niepel, Mario
    Hafner, Marc
    Duan, Qiaonan
    Wang, Zichen
    Paull, Evan O.
    Chung, Mirra
    Lu, Xiaodong
    Stuart, Joshua M.
    Golub, Todd R.
    Subramanian, Aravind
    Ma'ayan, Avi
    Sorger, Peter K.
    NATURE COMMUNICATIONS, 2017, 8
  • [34] Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling
    Mario Niepel
    Marc Hafner
    Qiaonan Duan
    Zichen Wang
    Evan O. Paull
    Mirra Chung
    Xiaodong Lu
    Joshua M. Stuart
    Todd R. Golub
    Aravind Subramanian
    Avi Ma’ayan
    Peter K. Sorger
    Nature Communications, 8
  • [35] Phospholipase A2 as targets for anti-cancer drugs
    Cummings, Brian S.
    BIOCHEMICAL PHARMACOLOGY, 2007, 74 (07) : 949 - 959
  • [36] An Assay Suitable for High Throughput Screening of Anti-Influenza Drugs
    Mao, Lili
    Wang, Jun
    DeGrado, William F.
    Inouye, Masayori
    PLOS ONE, 2013, 8 (01):
  • [37] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [38] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [39] Clinical Use of HER2 Extracellular Domain as a Marker to Monitor Cancer Status and Predict the Response to Anti-cancer Treatment in Breast Cancer
    Kontani, K.
    Hashimoto, S.
    Murazawa, C.
    Ohtani, M.
    Date, M.
    Yamauchi, A.
    Yokomise, H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S274 - S274
  • [40] A proposal for a novel system to evaluate and approve anti-cancer drugs
    Guirgis, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345